Publication

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.

Authors not recorded

Ann Oncol2019PMID 30624546PMC6386027stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (13)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 13

cancerGastrointestinal Stromal Tumorcivic_curation1.00
cancerLung Non-Small Cell Carcinomacivic_curation1.00
cancerSolid Neoplasmcivic_curation1.00
drugLarotrectinibcivic_curation1.00
geneNTRK1civic_curation1.00
geneNTRK3civic_curation1.00
variantNTRK1 Amplificationcivic_curation1.00
variantNTRK1 Fusioncivic_curation1.00
variantNTRK1 Fusioncivic_curation1.00
variantNTRK1 G595Rcivic_curation1.00
variantNTRK1 G667Scivic_curation1.00
variantNTRK3 F617Lcivic_curation1.00
variantNTRK3 Fusioncivic_curation1.00

Curated evidence

Evidence citing this paper (10)

civicCuratedShowing 1–10 of 10 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NTRK3 F617L2
Larotrectinib	Gastrointestinal Stromal Tumor	Predictive	C	Supports Resistance	2	accepted	EID9592 A 58-year-old male with NTRK-fusion positive gastrointestinal stromal tumour (GIST) demonstrated initial response to Larotrectinib but progressed after developing a gatekeeper mutation (TRKC F617L). PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic
〃	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Resistance	2	submitted	EID11571 In the LOXO-TRK-14001 trial, all eight patients with TRK-fusion positive cancer had objective response to larotrectinib. The FDA approval for this indication excludes patients with known resistance mu… (full text at CIViC) PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic
NTRK1 G595R + NTRK1 G667S1
Larotrectinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID9593 A 29-year-old male with NTRK-fusion positive NSCLC demonstrated initial response to Larotrectinib but progressed after devloping solvent-front (TRKA G595R) and xDFG (TRKA G667S) mutations. PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic
NTRK3 Fusion1
Larotrectinib	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	3	accepted	EID7496 In this phase 1 dose-escalation study seventy patients with metastatic solid tumours were enrolled. Eight patient tumours were found to harbour NTRK gene fusions, six of which were ETV6-NTRK3. Treatme… (full text at CIViC) PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic
NTRK1 Fusion1
Larotrectinib	Solid NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID9588 One patient was identified with a LMNA-NTRK1 positive tumor in this Phase I study (NCT02122913), which involved 70 heavily pretreated patients with a median age of 59.5 years, with multiple solid tumo… (full text at CIViC) PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic
NTRK1 Amplification1
Larotrectinib	Solid NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID10170 In a phase I study of larotrectinib in 67 patients with solid tumours, 8 patients were recorded as having objective response. 7 of these harboured NTRK fusions, and one had a NTRK1 amplification. This… (full text at CIViC) PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic
NTRK1 NTRK1 amplification1
Larotrectinib	Solid NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	rejected	EID10169 In a phase I study of larotrectinib in 67 patients with solid tumours, 8 patients were recorded as having objective response. 7 of these harboured NTRK fusions, and one had a NTRK1 amplification. This… (full text at CIViC) PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic
NTRK1 Point Mutations1
Larotrectinib	Solid NeoplasmCURATED_BROADER	Predictive	C	Does Not Support Sensitivity Response	2	submitted	EID9590 In this Phase I study (NCT02122913), which involved 70 heavily pretreated patients with a median age of 59.5 years, with multiple solid tumor types, None of the patients with NTRK point mutations had … (full text at CIViC) PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic
NTRK3 Point Mutations1
Larotrectinib	Solid NeoplasmCURATED_BROADER	Predictive	C	Does Not Support Sensitivity Response	2	submitted	EID9591 In this Phase I study (NCT02122913), which involved 70 heavily pretreated patients with a median age of 59.5 years, with multiple solid tumor types, None of the patients with NTRK point mutations had … (full text at CIViC) PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic
NTRK1 Fusion1
Larotrectinib	Solid NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID9589 This Phase I study (NCT02122913) enrolled 70 heavily pretreated adult patients (median age 59.5 years) with various advanced solid tumors. Among them, one patient was identified with a TPR::NTRK1 fusi… (full text at CIViC) PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic